Biogen
BIIB
969 hedge funds and large institutions have $58.9B invested in Biogen in 2015 Q4 according to their latest regulatory filings, with 139 funds opening new positions, 331 increasing their positions, 372 reducing their positions, and 82 closing their positions.
70% more first-time investments, than exits
New positions opened: 139 | Existing positions closed: 82
5% more funds holding
Funds holding: 923 → 969 (+46)
1% more capital invested
Capital invested by funds: $58.4B → $58.9B (+$503M)
0% more funds holding in top 10
Funds holding in top 10: 37 → 37 (0)
11% less repeat investments, than reductions
Existing positions increased: 331 | Existing positions reduced: 372
24% less call options, than puts
Call options by funds: $1.24B | Put options by funds: $1.63B
Top Buyers
| 1 |
D.E. Shaw & Co
New York
|
+$429M |
| 2 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$150M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$147M |
| 4 |
Millennium Management
New York
|
+$122M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$106M |
Top Sellers
BIIB Hedge Fund Activity: Q4 2015 in Review
969 of the 3,811 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2015, worth a combined $58.9B — up 0.86% from $58.4B a quarter earlier.
Buyers outnumbered sellers: 139 funds opened new BIIB positions and 82 closed out — a net gain of 57 holders — while 331 added to existing stakes and 372 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $429M. The largest seller was Fidelity Investments, cutting an estimated $1.05B.
- 969 institutional investors held Biogen (BIIB) as of Q4 2015, up from 923 in Q3 2015.
- Funds reported $58.9B of Biogen stock for Q4 2015, up 0.86% quarter-over-quarter.
- 139 funds opened new Biogen positions in Q4 2015 and 82 closed out, a net change of +57 holders.
- The largest Biogen buyer in Q4 2015 was D.E. Shaw & Co, an estimated $429M added.
- The largest Biogen seller in Q4 2015 was Fidelity Investments, an estimated $1.05B sold.
Based on aggregated 13F filings for Q4 2015.